# Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

> **NCT06107374** · PHASE2 · RECRUITING · sponsor: **CellSight Technologies, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** [18F]F-AraG

## Key facts

- **NCT ID:** NCT06107374
- **Lead sponsor:** CellSight Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107374, "Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06107374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*